Bisphosphonate-related osteonecrosis of the jaw in randomized clinical trials

Letter to the Editor


Breast Cancer Bisphosphonates Adjuvant Treatment Zoledronate Osteonecrosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0432-z
  2. 2.
    Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9(12):1166–1172CrossRefPubMedGoogle Scholar
  3. 3.
    Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54(5):1066–1072CrossRefPubMedGoogle Scholar
  4. 4.
    Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K (2009) Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Expert Review of Anticancer Therapy. doi: 10.1586/ERA.09.74
  5. 5.
    Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C, Boukovinas I, Koloutsos G, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Bisphosphonate related osteonecrosis of the jaws: a longitudinal cohort study of risk factors in cancer patients. J Clin Oncol. doi: 10.1200/JCO.2009.21.9584

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  1. 1.Aristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations